• Xueling Wang, Lin Han, and Jiyuan Yang.
• Department of Cardiovascular Medicine, Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, China.
• Medicine (Baltimore). 2022 Feb 18; 101 (7): e28848e28848.

BackgroundCoronary heart disease (CHD) has a high incidence rate as a cardiovascular condition, primarily affecting the elderly and middle-aged individuals. CHD has debilitating effects on the standard of life of the elderly, and affecting their physical and psychological health. Reportedly, using aspirin alone is less effective as a first line of treatment for CHD. Therefore, this systematic review and meta-analysis will synthesize evidence on the effectiveness and safeness of aspirin combination treatment in treating patients with CHD.MethodsA comprehensive meta-analysis is to be performed to evaluate the effectiveness and safety of aspirin combination treatment for CHD patients. A search will be performed on PubMed, EMBASE, Cochrane Central, WanFang, and Chinese National Knowledge Infrastructure till December 25, 2021 to identify randomized controlled trials, assess all related studies on the aspirin combination treatment in treating patients with CHD. In this systematic review, we will adopt the second version of Cochrane risk of bias assessment tool to assess the bias risk in all studies that fulfil the eligibility conditions. Two authors will separately conduct the study selection process, risk of bias assessment, and data extraction. Moreover, a random-effects meta-analysis will be conducted to synthesize evidence for all outcomes. Provided there is sufficient homogeneity among the studies, we will perform meta-analysis. I2 test will be employed to assess the heterogeneity of the outcomes.Osf Registration Number10.17605/OSF.IO/MDTCA.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

29 keywords...

hide…